A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-Line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-Treatment Period.

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT06524375
Trial Phases:	Phase II	Protocol IDs:
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Genentech Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT06524375

Summary

The main purpose of the study is to evaluate if adding venetoclax to participants
receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable
measurable residual disease [uMRD < or 10^-4 in peripheral blood (PB)] by end of
combination treatment (EOCT) to allow off-treatment period.

The acronym BRAVE stands for Btki Responders to Achieve deep remission (or off-treatment
periods) with VEnetoclax.

Treatment Sites in Georgia

University Cancer and Blood Center, LLC - Athens Medical Oncology
3320 Old Jefferson Road
Building 800
Athens, GA 30607
www.universitycancer.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.